Maridebart Cafraglutide
Also known as: AMG 133, MariTide
Antibody-peptide conjugate; GLP-1 receptor agonist / GIP receptor antagonist (bispecific)
What it is
Maridebart cafraglutide is an experimental weight-loss drug in clinical trials for obesity. It activates the GLP-1 pathway that curbs appetite while simultaneously blocking a second signal that promotes fat storage. Not FDA-approved; Phase 2 trials ongoing; early data show strong weight-loss results.
The scientific side
Maridebart cafraglutide (AMG 133) is a long-acting bispecific peptide-antibody conjugate engineered by conjugating a fully human monoclonal anti-human GIP receptor (GIPR) antagonist antibody to two GLP-1 analogue agonist peptides via amino acid linkers. It simultaneously activates GLP-1 receptors (GLP-1R agonism) and blocks GIP receptors (GIPR antagonism), combining complementary mechanisms of action in a single molecular entity. This dual mechanism is intended to enhance weight loss and improve metabolic parameters; both GIPR agonism (as in tirzepatide) and GIPR antagonism (as in maridebart cafraglutide) have paradoxically shown additive weight loss effects when combined with GLP-1R agonism (PMID 40507574, PMID 42166683). The antibody scaffold extends the plasma half-life beyond that of peptide-only approaches, enabling once-monthly subcutaneous dosing (PMID 42592044, PMID 40549887).
Class: Antibody-peptide conjugate; GLP-1 receptor agonist / GIP receptor antagonist (bispecific)
Administration & storage
- Administration
- Subcutaneous injection (PMID: 40549887)
- Storage
- Storage conditions for maridebart cafraglutide are not described in the reviewed abstracts.
- Cautions
- Gastrointestinal adverse events were common with maridebart cafraglutide in the phase 2 trial; they were less frequent with dose escalation and lower starting doses.,Maridebart cafraglutide is currently in clinical trial phases only; it is not an approved drug. Self-administration outside of supervised clinical study settings carries unknown risks.,No long-term human safety data beyond 52 weeks are reported in the reviewed abstracts. Long-term metabolic impacts of GIPR antagonism remain to be established.,Preclinical data indicated that GIPR antagonism reduced insulin sensitivity compared to pair-fed controls and reduced expression of adipose tissue lipolytic genes in obese male mice.,Sterile technique is essential for any subcutaneous injection to prevent infection.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Obesity (weight reduction) Mixed
- Phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial (n=465 in the obesity cohort). Mean percent change in body weight from baseline to week 52 ranged from -12.3% (95% CI -15.0 to -9.7) to -16.2% (95% CI -18.9 to -13.5) with maridebart cafraglutide vs. -2.5% (95% CI -4.2 to -0.7) with placebo. PMID 40549887 Jastreboff AM et al. New England Journal of Medicine (2025)
- Phase 1 randomized, double-blind, placebo-controlled study in participants with obesity demonstrated acceptable safety/tolerability and pronounced dose-dependent weight loss. In multiple ascending dose cohorts, weight loss was maintained for up to 150 days after the last dose. Preclinical data showed body weight reduct PMID 38316982 Véniant MM et al. Nature Metabolism (2024)
- Obesity with type 2 diabetes (weight reduction and glycemic control) Human RCT
- In the obesity-diabetes cohort (n=127), mean percent change in body weight from baseline to week 52 ranged from -8.4% (95% CI -11.0 to -5.7) to -12.3% (95% CI -15.3 to -9.2) with maridebart cafraglutide vs. -1.7% (95% CI -2.9 to -0.6) with placebo. Mean change in HbA1c ranged from -1.2 to -1.6 percentage points in the PMID 40549887 Jastreboff AM et al. New England Journal of Medicine (2025)
- Preclinical metabolic effects (obese mice and non-human primates) Animal studies only
- AMG 133 reduced body weight and improved metabolic markers in male obese mice and cynomolgus monkeys. GIPR antagonist and GLP-1R agonist activities were confirmed in cell-based systems. PMID 38316982 Véniant MM et al. Nature Metabolism (2024)
- Comparative study in male mice showed that a GIPR antagonist (NN-GIPR-Ant, representing the GIPR antagonism approach used in maridebart cafraglutide) reduced food intake and body weight in obese mice with more sustained appetite suppression vs. GIPR agonism, but also reduced insulin sensitivity compared to pair-fed con PMID 41287212 Davies I et al. Diabetes, Obesity & Metabolism (2026)
Safety signals
- Gastrointestinal adverse events were common with maridebart cafraglutide; frequency was reduced with dose escalation and lower starting doses. No unexpected safety signals were reported in the phase 2 trial. PMID 40549887
- Acceptable safety and tolerability profile reported in phase 1 study with pronounced dose-dependent weight loss and no unexpected safety signals described in the abstract. PMID 38316982
- In obese male mice, GIPR antagonism (the mechanistic approach used in maridebart cafraglutide) reduced insulin sensitivity compared to pair-fed controls and reduced adipose tissue lipolytic gene expression; slightly increased liver triglyceride content compared to pair-fed controls was also observed. PMID 41287212
Protocol
No community protocol on record. In clinical studies, Maridebart Cafraglutide was dosed at 140 mg, 280 mg, or 420 mg subcutaneously every 4 weeks (without dose escalation, or with 4-week or 12-week dose escalation); or 420 mg every 8 weeks (without dose escalation) Subcutaneous injection (PMID 40549887).
All studies (7)
- PMID 38316982 Mixed
Obesity (weight reduction) - PMID 40549887 Mixed
Obesity (weight reduction) - PMID 40507574
- PMID 41054801
- PMID 41287212 Animal studies only
Preclinical metabolic effects (obese mice and non-human primates) - PMID 42166683
- PMID 42592044
Frequently asked
What is maridebart cafraglutide and how does it work?
Maridebart cafraglutide (also called AMG 133 or MariTide) is a bispecific peptide-antibody conjugate. It works by combining GLP-1 receptor agonism with GIP receptor antagonism in a single molecule. A fully human monoclonal anti-GIPR antagonist antibody is conjugated to two GLP-1 analogue agonist peptides via amino acid linkers. The antibody scaffold extends the half-life, enabling once-monthly dosing. (PMID 38316982, PMID 42592044)
How much weight loss can I expect from maridebart cafraglutide?
In a phase 2 trial, participants with obesity (without type 2 diabetes) lost a mean of -12.3% to -16.2% of body weight over 52 weeks depending on dose and schedule, compared to -2.5% with placebo. Participants with obesity and type 2 diabetes lost a mean of -8.4% to -12.3% compared to -1.7% with placebo. These are trial-level group averages — individual results vary.
What dose of maridebart cafraglutide should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: The phase 2 trial tested doses of 140 mg, 280 mg, and 420 mg subcutaneously every 4 weeks, as well as 420 mg every 8 weeks, with or without dose escalation, over 52 weeks.
Is maridebart cafraglutide FDA-approved?
The reviewed scientific literature does not explicitly state the current FDA approval status of maridebart cafraglutide. The available abstracts describe it as being in phase 1 and phase 2 clinical trials. Regulatory status requires manual verification with official FDA sources.
What are the side effects of maridebart cafraglutide?
The most commonly reported adverse events in clinical studies were gastrointestinal in nature. These were less frequent when a lower starting dose or dose escalation schedule was used. The phase 2 trial reported no unexpected safety signals. A phase 1 study also described an acceptable safety and tolerability profile.
How is maridebart cafraglutide different from tirzepatide (Mounjaro/Zepbound)?
Both drugs target GLP-1 and GIP pathways but in opposite ways for GIP: tirzepatide is a GLP-1R/GIPR dual agonist (activates both receptors), while maridebart cafraglutide combines GLP-1R agonism with GIPR antagonism (activates GLP-1R but blocks GIPR). Paradoxically, both approaches have shown significant weight loss in humans. Maridebart cafraglutide is also an antibody-peptide conjugate enabling once-monthly dosing, whereas tirzepatide is a weekly peptide injection. (PMID 42166683, PMID 41054801, PMID 40549887)
Can I stack maridebart cafraglutide with other peptides or compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Maridebart cafraglutide has been studied as a standalone agent in phase 1 and phase 2 trials (PMID 38316982, PMID 40549887). No combination studies are reported in the reviewed literature.
Does maridebart cafraglutide help with type 2 diabetes?
In the phase 2 trial, participants with obesity and type 2 diabetes experienced mean HbA1c reductions of -1.2 to -1.6 percentage points with maridebart cafraglutide, compared to +0.1 percentage points with placebo. Weight loss of -8.4% to -12.3% was also observed in this group.
Where can I buy maridebart cafraglutide?
I don't recommend vendors or sources. Please consult a licensed provider. Note that maridebart cafraglutide is an investigational compound being evaluated in clinical trials and is not known to be approved for commercial sale based on the reviewed literature.
How long does the weight loss effect last after stopping maridebart cafraglutide?
A phase 1 study reported that weight loss was maintained for up to 150 days after the last dose in multiple ascending dose cohorts. Longer-term data after discontinuation are not reported in the reviewed abstracts.